Conatus Pharmaceuticals Inc. buy tamam
Start price
24.09.15
/
50%
€59.64
Target price
24.03.16
€80.91
Performance (%)
-69.00%
End price
24.03.16
€18.49
Summary
This prediction ended on 24.03.16 with a price of €18.49. The BUY prediction by tamam for Conatus Pharmaceuticals Inc. performed very badly with a performance of -69.00%. tamam has 50% into this predictionPerformance without dividends (%)
| Name | 1w | 1m | 1y | 3y |
|---|---|---|---|---|
| Conatus Pharmaceuticals Inc. | - | - | - | - |
| iShares Core DAX® | 0.463% | -1.999% | 9.981% | 58.545% |
| iShares Nasdaq 100 | -1.792% | -5.743% | -0.781% | 80.511% |
| iShares Nikkei 225® | 5.124% | 9.091% | 28.823% | 62.776% |
| iShares S&P 500 | -1.760% | -3.669% | -0.543% | 54.389% |
Comments by tamam for this prediction
In the thread Conatus Pharmaceuticals Inc. diskutieren
tamam stimmt dem eigenen Sentiment von 'Buy' zu
tamam stimmt am 24.09.2015 dem Buy-Crowdsentiment mit dem Kursziel 8.97$ zu.
Top-line results from a 23-subject Phase 2 clinical trial assessing Conatus Pharmaceuticals' (NASDAQ:CNAT) lead product candidate emricasan for the treatment of portal hypertension in patients with liver cirrhosis successfully demonstrated efficacy as determined by two outcome measures.
(Laufzeit überschritten)